10

Loading video...

John Mulder

By John Mulder

0

Share

Newsweek is a Trust Project member

See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.


A reassuring health check can leave a dangerous question unanswered: What has been happening inside the body over the years? We must broaden prevention by looking beyond today’s blood pressure, glucose, and cholesterol readings to the accumulated metabolic burden that may be building silently in our tissues.

That means taking metabolic memory seriously, investigating unexpected findings, and acting before disease announces itself.

Routine tests are indispensable. Blood pressure, blood glucose, HbA1c, and inflammatory markers help clinicians identify problems and guide treatment.

Read More on Leadership Insights

But they are snapshots, not a complete history. Two people can have similar results today despite very different exposure to metabolic stress over many years. A normal result should reassure us only as far as that measurement allows.

Undated file image of senior females having their blood pressure tested at a mobile medical clinic.

...

The Importance of Metabolic Memory

One part of the missing history is metabolic memory: the lasting biological imprint of earlier metabolic stress. As explained in a study indexed by the National Library of Medicine, advanced glycation end-products, or AGEs, form when sugars react with proteins or fats.

They accumulate in body tissues over time and are associated with cardiovascular disease, diabetes, and kidney disease. Their presence can offer a window into long-term tissue burden that a current blood test may not capture.

This is not an argument for discarding established tests or treating one new measurement as a diagnosis. It is an argument for asking whether our picture of risk is complete.

A 2026 meta-analysis in the European Journal of Medical Research found that elevated skin autofluorescence, a measure linked to tissue AGE accumulation, was associated with higher risks of cardiovascular events, cardiovascular death, stroke, and death from any cause.

The authors also stressed that further work is needed to establish how much this measure adds to existing risk scores and how it should guide decisions.

That distinction matters. An association is not proof that a test can predict an individual’s future, and an elevated result should prompt clinical judgment, not panic. But neither should an unexpected signal be ignored simply because conventional results look reassuring.

In cardiovascular screening, the gap between a low calculated risk and a higher underlying tissue burden deserves closer study. The scale of this mismatch must be established through well-designed studies, not asserted through an unverified percentage.

Undated file image of a nurse holding a printout of a patient's heart rate in the stress test room at Mt. Diablo Medical Center in Concord, California.

...

The stakes are personal and public. If we look only for disease that has already crossed a familiar threshold, we risk missing opportunities to investigate early deterioration. Patients may receive reassurance when a fuller assessment would justify follow-up. Health systems may then face the expensive consequences of conditions that could have been addressed earlier.

The alternative is a prevention system that sees more of the patient’s biological history, investigates warning signs, and makes timely, proportionate decisions.

Cardiovascular Prevention Must Keep Improving

The urgency is clear in the latest wider evidence.

The American Heart Association’s 2026 Heart Disease and Stroke Statistics report says cardiovascular disease and stroke together accounted for more than a quarter of all deaths in the United States in 2023. That is a reminder that cardiovascular prevention must keep improving, especially when the burden remains so high.

So, what should clinicians do when a new measure and familiar markers disagree? First, dig deeper. Review the patient’s history and investigate what might explain the discrepancy. Second, refer appropriately when the question falls beyond their expertise. Third, reconsider the prevention or treatment plan, intensifying it only where the wider clinical picture supports that decision.

A measurement has value only when it leads to an informed response.

Researchers must keep testing these markers, defining their limits, and showing when they improve decisions and outcomes. Medical education should give metabolic memory and tissue burden greater attention. Clinicians should remain curious when results do not fit together. And patients should ask what their routine numbers do, and do not, tell them.

We can build a future in which risk is recognized earlier and prevention is more personal, precise, and timely. Or we can keep mistaking a normal snapshot for the whole story, until silent damage becomes visible as disease.

We do not need to abandon the measurements medicine already trusts. We need to stop assuming they tell us everything.

John Mulder is a healthcare innovation leader and CEO of Diagnoptics, a Netherlands-based medical technology company focused on noninvasive assessment of metabolic and cardiovascular risk. All views expressed are the author's own.

View 0 Comments

Request Reprint & Licensing

Submit Correction

View Editorial & AI Guidelines